Scale-Up & Pilot Plant Patents: Leaders, Trends & White Space 2026
- 7.5% concentration at the top. The five leading assignees together hold 3,528 of 46,909 records in scope — a real edge, but nowhere near control of the field.
- Filings cooled after a 2022 peak. Volume ran from 1,158 in 2021 down to 726 in 2024, a 37% pullback over that span, though the two most recent years are still filling in as publications catch up.
- Medicinal-preparations claims dominate the class mix. A61K appears on 14.9% of all records, more than double the next class, meaning most scale-up patenting here traces back to biologic and drug-substance production rather than pure process engineering.
Filing growth compares 2021 (1,158 records) with 2024 (726) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 46,909 records in scope (CR5), not by the ranked leaders only.
What the scale-up and pilot plant patent record actually covers
Scale-up and pilot plant engineering sits at the junction of two things patent examiners classify differently: the chemistry or biology being produced and the process equipment used to make more of it. This search pulls records that combine explicit scale-up language with process-engineering terms — residence time, particle size, mass transfer, chemical reactor — so the resulting set spans everything from aerosol flame reactors making nanoparticles to bioreactor protocols for cell therapy manufacturing.
That breadth shows up in the technology mix: medicinal preparations and microorganism/genetic-engineering classes sit alongside catalysis, separation and heterocyclic-compound classes. A record can carry several IPC codes at once, so the field is best read as overlapping claim territories rather than a single technology stack.
Let an AI agent run this analysis on your own technology
Pick a task. Every answer cites the patents behind it.
Filing trend and technology composition
46,909 records sit in scope, spanning receiving offices from the USPTO through EPO, WIPO/PCT, and national offices in Australia, Canada and Singapore.
Filing activity peaked in 2022, then pulled back
Annual filings rose from 994 in 2017 to a peak of 1,160 in 2022, then declined to 726 by 2024 — a 37% drop across the 2021-2024 window. 2025 and 2026 figures are still incomplete because publication typically lags filing by about 18 months, so the apparent decline in the newest years should not be read as the field's current trajectory.
Medicinal preparations and cell engineering lead the class mix
A61K (medicinal preparations) appears on 14.9% of the 46,909 records in scope, with C12N (microorganisms and genetic engineering) at 6.5% and B01J (chemical/physical processes and catalysis) at 5.8%. Separation processes (B01D, 3.5%) and heterocyclic compounds (C07D, 3.8%) round out a mix that is weighted toward biologic and pharmaceutical production rather than bulk chemical processing.
Shares are the percentage of the 46,909 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Scale-Up & Pilot Plants Patent Landscape with Eureka
This page is one run against one query. Ask Eureka your own question about scale-up & pilot plants patent landscape and every answer comes back with the patent numbers behind it.
Try EurekaThe most-cited records anchoring this field
System for Optimizing and Controlling Particle Size Distribution and for Scale-Up of Nanoparticle Production in an Aerosol Flame Reactor
The filing describes a system for optimizing and controlling particle size distribution during scale-up of nanoparticle production in an aerosol flame reactor. It couples a flame dynamics model with a particle population balance model inside a simulation tool, using programmed instructions to hold particle size and specific surface area within a target range as production is scaled.Filed by Tata Consultancy Services, dated 2012-01-12 — a rare example of a scale-up claim built entirely around a simulation-driven control method rather than a physical reactor design.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US6797514B2 | Simultaneous stimulation and concentration of cells | 1,996 |
| 2 | US6867041B2 | Simultaneous stimulation and concentration of cells | 1,972 |
| 3 | US6905874B2 | Simultaneous stimulation and concentration of cells | 1,966 |
| 4 | WO2014093622A2 | Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and the… | 1,492 |
| 5 | US20060121005A1 | Activation and expansion of cells | 1,326 |
| 6 | US20170041296A1 | Systems and methods of secure data exchange | 1,323 |
| 7 | US20140179770A1 | Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and the… | 981 |
| 8 | US20160208243A1 | Novel crispr enzymes and systems | 863 |
| 9 | US9790490B2 | CRISPR enzymes and systems | 757 |
| 10 | US20150310188A1 | Systems and methods of secure data exchange | 728 |
Citation counts reflect an older-skews-higher bias within this searched corpus — treat them as a marker of influence on later filings, not of present-day relevance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the numbers mean for filing strategy
Three patterns stand out once the record set is broken down by class, citation weight and filing year.
The top of the field is thin
The five leading assignees together hold 3,528 records, 7.5% of all 46,909 in scope. That is a meaningful lead but far short of dominance — the remaining ranked leaders and a long tail of single- and few-filing entrants hold the rest, which means freedom-to-operate analysis has to look well past the household names.
Influence clusters around cell-processing patents
The most-cited records in this set — led by patents on simultaneous stimulation and concentration of cells — are older filings that predate much of the current biologic-manufacturing wave. Their citation counts reflect years of accumulated reference, not that the underlying method is still the state of the art.
Volume has pulled back from its 2022 peak
Filings peaked at 1,160 in 2022 and fell to 726 by 2024. The drop is real across a complete three-year window, but it should not be extended into 2025-2026: those years are still under-published and will fill in as the 18-month publication lag closes.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to scale-up & pilot plants patent landscape, with the prior art for and against each one.
Assignee landscape and where the open ground sits
The ranked field covers 100 assignees; the leader holds 1,087 records, with the fifth-ranked company at 470 and the tenth at 315 — a steep early drop-off followed by a long, flatter tail.
A clear leader, not a monopoly
The top assignee's 1,087 records outpace the fifth-place holder's 470 by more than double, but the top 10 combined still account for only 11.2% of all 46,909 records in scope. Most of the field's claim space sits outside the leaders' portfolios.
Research-institute pairs dominate co-assignment
The strongest co-assignee link in this dataset — 617 shared records — sits between two research institutes rather than between a research institute and an industrial partner, pointing to academic-led programs that later license out rather than joint industrial scale-up ventures.
Leading filers have slowed sharply in the most recent year
Several of the most active historical assignees show filings down 90% or more year-on-year in the latest year, with some at zero. Given the publication lag, this reads more as an artefact of incomplete recent data than a genuine retreat from the field.
| Assignee | Recent year | YoY |
|---|---|---|
| Massachusetts Institute of Technology (MIT) | 2 | -90% |
| The Broad Institute, Inc. | 2 | -90% |
| President and Fellows of Harvard College | 0 | -100% |
| ModernaTX, Inc. | 0 | -100% |
| Janssen Biotech, Inc. | 0 | -100% |
| Vertex Pharmaceuticals Incorporated | 0 | — |
| Commonwealth Scientific and Industrial Research Organisation (CSIRO) | 0 | — |
| AbbVie Inc. | 0 | -100% |
Where to take this analysis
The dataset points to a field with a modest leadership cluster and substantial open ground. Two directions make sense from here.
Map claim boundaries around the leading assignees
With the top 10 holding only 11.2% of records, a freedom-to-operate review needs to go past the household names into the long tail of single- and few-filing entrants that make up the bulk of the field.
Explore assignee portfolios in EurekaTrack the under-claimed process branches
Separation-stage and catalyst mass-transfer scale-up show thinner filing density than the medicinal-preparations core. That gap is worth monitoring before it fills in, particularly as recent-year data completes.
Set up a white-space monitor in EurekaCommon questions about scale-up and pilot plant patents
The ranked field covers 100 assignees, with the leader holding 1,087 records and the fifth-ranked company at 470. The top five together account for 3,528 records, 7.5% of the 46,909 records in scope, which is a real advantage but not control of the field. Beyond the top ten, filing spreads across a long tail of companies and institutions with far fewer records each, so a full competitive view has to look past the leaderboard.
Filings rose from 994 in 2017 to a peak of 1,160 in 2022, then fell to 726 by 2024 — a 37% decline over that three-year window. That is a genuine pullback across complete data years. The 2025 and 2026 figures look lower still, but publication typically lags filing by about 18 months, so those years are undercounted rather than necessarily weaker.
Medicinal preparations (A61K) appear on 14.9% of the 46,909 records in scope, well ahead of microorganism and genetic-engineering claims (C12N, 6.5%) and catalysis-related processes (B01J, 5.8%). This tells you the field, as captured by this search, leans heavily toward biologic and pharmaceutical production scale-up rather than bulk industrial chemistry. Separation processes and heterocyclic-compound claims make up smaller but still notable shares.
US20120009118A1, filed by Tata Consultancy Services, describes a system for optimizing and controlling particle size distribution during scale-up of nanoparticle production in an aerosol flame reactor. Its core mechanism couples a flame dynamics model with a particle population balance model inside a simulation tool driven by programmed instructions. It is notable for building the scale-up claim around a simulation-and-control method rather than a specific reactor hardware design, which shapes how narrowly or broadly it can be read against adjacent filings.
Separation-process scale-up (B01D, 3.5% of records) and catalyst mass-transfer scaling sit well below the medicinal-preparations core in filing density, suggesting thinner claim coverage there relative to their engineering importance. Continuous-flow residence-time control and aerosol/flame reactor particle-size modelling also show comparatively light concentration among the leading assignees. These are reasonable starting points for a claim search, though thinner filing density should be confirmed against a fresh landscape before committing R&D spend.
Research Scale-Up & Pilot Plants Patent Landscape in depth with Eureka
Go past this page: query the whole scale-up & pilot plants patent landscape corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.